Amyotrophic Lateral Sclerosis (ALS)
116
30
34
43
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
15 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.4%
4 terminated out of 116 trials
91.5%
+5.0% vs benchmark
10%
12 trials in Phase 3/4
35%
15 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 43 completed trials
Clinical Trials (116)
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases
A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Study of COYA 302 for the Treatment of ALS
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Intestinal Microbiome Transplant in ALS
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS
HEALEY ALS Platform Trial - Regimen I NUZ-001
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Retinal Imaging in Neurodegenerative Disease
Quantification of Hsp90 in the Human Brain
Healing ALS Registry Observational Study (HAROS)
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis